Fig. 1: The upregulation of Pla2g7 is associated with bone loss in human and mice.

A Uniform manifold approximation and projection (UMAP) plot showing the main cell types of the single-cell RNA sequencing dataset and the enrichment of Pla2g7 in the main cell types. B The expression of Pla2g7 in the main cell types of bone tissue from human. C The expression of Pla2g7 during the differentiation from osteoblast to osteocyte. D, E The expression of Pla2g7 in pre-osteoclasts and osteoclasts with the RANKL-induced time gradient. F, G The gene and protein expression of Pla2g7, Nfatc1 and c-Fos in response to RANKL-induced time gradient, and the densitometric analysis of Western blot bands. For RNA analysis, n = 3 biologically independent wells per group, for Western blot analysis, n = 3 biologically independent cell samples per group. H Immunohistochemistry staining images of femur in OVX model and metatarsus in K/BxN model. Cells labeled in red are Pla2g7-positive. (Scale bar, OVX models, 200 μm. K/BxN models, 100 μm). I Quantification of immunohistochemistry staining in Pla2g7 positive cells. n = 6 biologically independent mice per group. J Elisa detection of Pla2g7 concentration in normal patients (NP) and osteoporosis patients (OP). NP, n = 75. OP, n = 75. Each n represents one independent patient. K Pla2g7 concentration in Sham and OVX groups. n = 6 biologically independent mice per group. Data were showed as mean ± SD. Two-sided Student’s t test (I–K) was employed to assess the difference between the two groups. One-way ANOVA (F, G) was utilized for multiple comparisons test. Significance: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001, ns non-significance.